Results 261 to 270 of about 127,480 (296)

The safety of treatment options for acute bacterial skin and skin structure infections

Expert Opinion on Drug Safety, 2019
Acute bacterial skin and skin-structure infections (ABSSSI) may develop in both in-patients and out-patients, possibly with a severe clinical presentation. Since most phase 3 randomized clinical trials have shown non-inferiority in efficacy across different agents, considerations regarding their different safety profiles inevitably play a crucial role ...
Bassetti M., Peghin M., Castaldo N., Giacobbe D. R.   +3 more
openaire   +4 more sources

Novel developments in the treatment of acute bacterial skin and skin structure infections

Expert Opinion on Pharmacotherapy, 2019
Introduction: Acute bacterial skin and skin structure infection (ABSSSI) represents a major burden for healthcare systems. The increased prevalence of Methicillin-resistant Staphylococcus aureus, combined with the limited availability of microbiologic data when treating ABSSSI, has led to a need for more convenient, less toxic anti-MRSA agents.
Rupal K, Jaffa, Kelly E, Pillinger, Danya, Roshdy, Jacqueline A, Isip, Timothy R, Pasquale   +4 more
openaire   +2 more sources

Current and emerging drugs for acute bacterial skin and skin structure infections: an update

Expert Opinion on Emerging Drugs, 2014
Antibiotic resistance, the emergence of multidrug-resistant bacteria and the exponential rise of methicillin-resistant Staphylococcus aureus (MRSA) acute bacterial skin and skin structure infections (ABSSSI) pose a great threat to the public health.
Ramya, Kollipara, Christopher, Downing, Michael, Lee, Jacqueline, Guidry, Stephen, Curtis, Stephen, Tyring   +5 more
openaire   +2 more sources

Potential role of new-generation antibiotics in acute bacterial skin and skin structure infections

Current Opinion in Infectious Diseases, 2020
Purpose of review To summarize the available results of primary analyses from high-quality randomized studies of either recently approved or possible future agents for the treatment of acute bacterial skin and skin structure infections (ABSSSI). Recent findings In the last 2 decades,
Giacobbe, Daniele R, Labate, Laura, Vena, Antonio, Bassetti, Matteo   +3 more
openaire   +2 more sources

Acute bacterial skin and skin structure infections in internal medicine wards: old and new drugs

Internal and Emergency Medicine, 2016
Skin and soft tissue infections (SSTIs) are a common cause of hospital admission among elderly patients, and traditionally have been divided into complicated and uncomplicated SSTIs. In 2010, the FDA provided a new classification of these infections, and a new category of disease, named acute bacterial skin and skin structure infections (ABSSSIs), has ...
FALCONE, MARCO, Concia, Ercole, GIUSTI, Massimo, Mazzone, Antonino, SANTINI, CLAUDIO, STEFANI, STEFANIA, VIOLI, Francesco   +6 more
openaire   +3 more sources

The optimal duration of treatment for skin and soft tissue infections and acute bacterial skin and skin structure infections

Current Opinion in Infectious Diseases, 2018
Purpose of review To summarize the current finding on SSTIs/ABSSSIs treatment duration. Recent findings In 2013, the FDA approved the definition of acute bacterial skin and skin structure infections (ABSSSIs).
Corcione, Silvia, De Rosa, Francesco Giuseppe   +1 more
openaire   +2 more sources

Dalbavancin: A Review in Acute Bacterial Skin and Skin Structure Infections

Drugs, 2015
Intravenous dalbavancin (Dalvance™; Xydalba™) is approved for use in adult patients with acute bacterial skin and skin structure infections (ABSSSI), with the recommended regimen being a 1000 mg dose followed 1 week later by a 500 mg dose. In the multinational DISCOVER 1 and 2 trials in adult patients with ABSSSI, dalbavancin treatment was noninferior ...
openaire   +2 more sources

Delafloxacin meglumine for the treatment of acute bacterial skin and skin structure infections (ABSSSI)

Drugs of Today, 2018
Delafloxacin meglumine (Baxdela, WQ-3034, ABT-492, RX-3341; Melinta Therapeutics) was approved by the U.S. Food and Drug Administration (FDA) in June 2017 for the treatment of acute bacterial skin and skin structure infections on the basis of data from two phase III trials.
G, Kaul, E, Kapoor, A, Dasgupta, S, Chopra   +3 more
openaire   +2 more sources

Single-Dose Dalbavancin: A Review in Acute Bacterial Skin and Skin Structure Infections

Drugs, 2016
Intravenous dalbavancin (Dalvance®, Xydalba®), first approved as a two-dose regimen for the treatment of acute bacterial skin and skin structure infections (ABSSSI), has now been additionally approved as a single-dose regimen. This narrative review discusses the pharmacological properties of intravenous dalbavancin and its clinical efficacy and ...
openaire   +2 more sources

New antibiotics in the management of acute bacterial skin and skin structure infections.

Skin therapy letter, 2016
Acute bacterial skin and skin-structure infections (ABSSSIs), often caused by aerobic gram-positive cocci, are most often mild-tomoderate infections that can easily be treated in an outpatient setting. With the rates of these infections substantially increasing in the past decade, owing in part to the emergence of community acquired methicillin ...
K, Gleghorn, E, Grimshaw, E K, Kelly
openaire   +1 more source